ClinicalTrials.gg
RecruitingNCT06704945Neo-NAUTILUSUpdated Jan 28, 2026

No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy

A Phase 3 interventional study of No axillary surgery and Axillary surgery in Breast Cancer, Neoadjuvant Therapy and Sentinel Lymph Node Biopsy, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Seoul National University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Breast Neoplasms by Seoul National University Hospital — 13 open to participants now, 21 under way, 3 of them phase 3. Breast Neoplasms · Seoul National University Hospital.

Planned enrollment
4th of 28
464 · median 114
Started
2025
with 2 others
Phase 3
5 of 50
3 open now
Primary completion
2029-12
later than 20 of 20 live
Registered
49th of 50
by date

Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, this one is the 4th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 20 of the 20 other live ones, and was the 49th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 50 studies in Breast Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Breast Neoplasms by Seoul National University Hospital, or all of them as a file.
02

Study summary

NEO-NAUTILUS is a prospective, multicenter, randomized phase III clinical trial to evaluate whether omitting axillary lymph node surgery (ALND or SLNB) in clinically lymph node-negative breast cancer patients after neoadjuvant chemotherapy is non-inferior to performing SLNB in terms of 5-year disease-free survival.

Read the detailed description

Background:

  • No prospective studies have proven that axillary lymph node surgery improves survival in breast cancer patients.
  • The ACOSOG Z0011 trial showed that additional axillary dissection did not improve recurrence or survival, even with a 23.7% incidence of non-sentinel node metastases.
  • NSABP B-32 established the oncologic safety of SLNB, significantly reducing complications like lymphedema compared to axillary dissection. However, SLNB still carries risks of lymphedema, sensory changes, seromas, and infections.
  • The trend has now shifted toward identifying candidates for omitting axillary surgery to minimize unnecessary complications.
  • The SOUND trial demonstrated non-inferiority of omitting SLNB in early-stage breast cancer patients with negative axillary ultrasound. Five-year distant metastasis-free survival was comparable between SLNB and no-SLNB groups (97.7% vs. 98.0%).
  • Improved ultrasound accuracy (e.g., FNR: 13.7% in SOUND; 11.3% in NAUTILUS) and the therapeutic contribution of whole-breast radiation likely support these findings.
  • Patients with a complete pathological response (pCR) in the breast post-NAC rarely have residual lymph node metastases, reducing the need for axillary surgery.
  • Single-arm studies (e.g., EUBREAST-01, ASICS, ASLAN) have explored omitting axillary surgery in patients with confirmed breast pCR. However, these studies face limitations due to small sample sizes, single-arm design, and the necessity of axillary surgery if pCR is not achieved.
  • To address these limitations, the NEO-NAUTILUS trial proposes the first randomized trial to compare disease-free survival and local recurrence rates between patients who omit SLNB (experimental group) and those who undergo SLNB (control group) after NAC, focusing on patients deemed axillary node-negative by ultrasound.
03

Conditions studied

  • Breast Cancer
  • Neoadjuvant Therapy
  • Sentinel Lymph Node Biopsy

Browse trials for

Keywords

  • Omission of axillary surgery after neoadjuvant chemotherapy
  • Breast cancer
  • Neoadjuvant chemotherapy
  • De-escalation
  • Omission of surgery
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged ≥19 years.
  • confirmed invasive breast carcinoma treated with chemotherapy.
  • Clinical staging prior to NAC: cT1-3, cN0, M0 (AJCC 8th Edition).
  • If pre-NAC staging is cT1-3, cN1, M0, must meet the following criteria:

    1. -positive or triple-negative breast cancer (TNBC).
    2. At least 30% reduction in tumor size on MRI after NAC (comparing pre- and post-NAC MRI).
  • Negative axillary lymph node status on ultrasound after NAC.
  • Planned for breast-conserving surgery with completed neoadjuvant chemotherapy (at least half the planned regimen must be completed).
  • performance status of 0-2.
  • Signed written before enrollment.

Exclusion criteria

Exclusion Criteria:

  • History of any cancer within the past 5 years.
  • Bilateral breast cancer.
  • Patients requiring mastectomy.
  • Tumor size >5 cm after NAC.
  • Male breast cancer.
  • Pregnant or breastfeeding women.
  • Inability to understand and complete questionnaires.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
464 participants (estimated)

Study arms

  • Experimental
    No SLNB group

    The study arm - BCS without SLNB

    Procedure: No axillary surgery

  • Other
    SLNB group

    The control arm - BCS with SLNB(+/-ALND)

    Procedure: Axillary surgery

Interventions

  • ProcedureNo axillary surgery

    BCS only. Ommission of axillary surgery. No axillary surgery after neoadjuvant chemotherapy.

  • ProcedureAxillary surgery

    BCS with SLNB(+/-ALND)

06

What researchers measure

Primary outcomes

  1. Invasive Disease Free Survival (iDFS)

    Evaluate invasive disease free survivals

    Time frame: 5 years

Secondary outcomes

  1. Overall Survival (OS)

    Evaluate overall survival

    Time frame: 5 years

  2. Distant Metastasis Free Survival (DMFS)

    Evaluate distant metastasis free survival

    Time frame: 5 years

  3. Axillary recurrence rate

    Evaluate ipsilateral axillary recurrence rate

    Time frame: 5 years

  4. Locoregional Recurrence Rate (LRR)

    Evaluate locoregional recurrence rate

    Time frame: 5 years

  5. QoL

    Evaluate Quality of Life of patient by EORTC QLQ-C30 questionnaire

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hopsital
    Seoul, 03080, South Korea
    Recruiting
08

References and documents

Publications

  • Jung JG, Ahn SH, Lee S, Kim EK, Ryu JM, Park S, Lim W, Jung YS, Chung IY, Jeong J, Chang JH, Shin KH, Chang JM, Moon WK, Han W. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial. BMC Cancer. 2022 Feb 20;22(1):189. doi: 10.1186/s12885-022-09273-1. PubMed 35184724 ↗
  • Jung JJ, Kim HJ, Chae BJ, Kim EK, Ahn JH, Jeong J, Lee S, Jung SP, Woo J, Min J, Cheun JH, Chung MS, Shin KH, Chang JM, Moon WK, Han W. A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer. J Breast Cancer. 2025 Dec;28(6):437-447. doi: 10.4048/jbc.2025.0157. Epub 2025 Nov 14. PubMed 41311332 ↗

Individual participant data

Plan to share: Yes — Study protocol will be shared.

Supporting information: Study protocol

Time frame: The study protocol will be published as a journal article.

Access criteria: Anyone interested in viewing the study protocol will be able to access it through the published journal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2029, 54 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 54 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 26, 2024
StartActual
Jun 4, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2034
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704945
Collaborators
Asan Medical Center
Responsible party
Wonshik Han (Professor, Seoul National University Hospital) — Principal investigator
First posted
Nov 26, 2024
Start date
Jun 4, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Jan 28, 2026

Study contacts

Wonshik Han, MD, PhD.
Contact
hanw@snu.ac.kr
82-2-3461-6060

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion